Skip to content
Open access

Age-related differences in treatment and outcomes among women with breast cancer: a real-world cohort study

2026 · Mastology · 0 citations

Abstract

Background: As the breast cancer population ages, understanding how age influences treatment decisions and survival in real-world settings becomes increasingly relevant. Age-related differences in clinicopathological features, treatment patterns, and outcomes were evaluated among women with surgically treated invasive breast cancer at a Brazilian public high-complexity referral center. Methods: This retrospective cohort study included women aged 50 years or older with invasive breast cancer treated surgically between 2020 and 2024. Patients were stratified into three age groups: 51–69 years, 70–74 years, and ≥75 years. Clinicopathological variables, treatment patterns, recurrence, overall survival (OS), and disease-free survival (DFS) were compared across groups using standard statistical methods. The study was approved by Plataforma Brazil (CAAE 87347725.8.0000.5463). Results: A total of 2,148 patients were analyzed: 1,335 aged 51–69 years, 405 aged 70–74 years, and 408 aged ≥75 years. Treatment intensity declined progressively with age. Rates of neoadjuvant chemotherapy were 28.3%, 20.7%, and 10.3%, respectively; adjuvant chemotherapy, 28.3%, 22.2%, and 6.6%; and radiotherapy, 85.8%, 63.0%, and 36.0% (all p<0.001). In contrast, the oldest group showed the worst outcomes, with higher locoregional recurrence (2.2%, 3.0%, and 8.1%; p=0.001), overall recurrence (2.2%, 3.0%, and 7.4%; p=0.004), and death rates (4.0%, 2.2%, and 10.3%; p=0.005). OS and DFS were significantly poorer with advancing age (OS, p=0.002; DFS, p<0.001). In multivariable analysis, triple-negative subtype, mastectomy, and axillary dissection were associated with higher mortality, while radiotherapy showed a protective effect. Conclusions: Women aged 75 years or older had more unfavorable outcomes and received less intensive treatment, suggesting that advanced age remains strongly associated with poorer real-world breast cancer outcomes. These findings highlight the need for more individualized, evidence-based treatment strategies to avoid undertreatment in older patients.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.